Intended for healthcare professionals

Letters Industry payments and low value cancer drugs

Use of denosumab in castration sensitive prostate cancer

BMJ 2023; 383 doi: (Published 04 December 2023) Cite this as: BMJ 2023;383:p2827
  1. Michaël R Laurent, consultant geriatrician
  1. Imelda Hospital, Bonheiden, Belgium
  1. michael.laurent{at}

In their article, Mitchell and colleagues state that the use of denosumab in men with castration sensitive metastatic prostate cancer who lack an appropriate indication (such as osteoporosis) constitutes non-recommended, low value care.1

Standard treatment for this group of patients, however, is androgen deprivation therapy, which inherently carries an increased risk …

View Full Text

Log in

Log in through your institution


* For online subscription